A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Exclusion Criteria

• •1. Prior anti-cancer treatment with any HSP90 inhibitor
• •2. Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
• •3. Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years
• •4. Abnormal heart function
• •5. Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
• •6. Hypersensitivity of AT13387 or other components of the drug product
• •7. Treatment with an investigational drug within 3 weeks prior to the first dose of study drug
• •8. Severe systemic diseases or active uncontrolled infections
• •9. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus